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• Mast cells play a central role not only in type I hyper- 
sensitivity reactions, but also in chronic inflammatory pro- 
cesses resulting in fibrosis. Fibrosis is a process character- 
ized by fibrob last proliferation and/or by excessive production 
and deposition of collagen and other extracellular matrix 
components. The close proximity of mast cells andfibroblasts 
in the connective tissue enables the interaction between these 
two cell types. Fibroblasts have been shown to provide the mi- 
croenvironmentfor connective tissue mast cell differentiation 
and survival. On the other hand, mast cells can affect fibro- 
blasts through the release of various mediators with either fi- 
brogenic or fibrolytic activities. Mast cells were shown to be 
present in active form in various fibrotic conditions such as 
scleroderma, chronic graft-versus-host disease, eosinophilic 
fasciitis, wound healing, idiopathic pulmonary fibrosis, and 
ocular cicatricial pemphigoid. This review presents the cur- 
rent data about mast cell and these fibrotic disorders. 
INTRODUCTION 
• Mast cells (MC) are tissue dwelling cells which contain 
prominent cytoplasmic granules that characteristically stain 
metachromatically with cationic dyes and possess surface recep- 
tors for diferent ligands, including irnmunoglobulin E (IgE). 
These cells are widely distributed in the body, being found in 
skin connective tissue and in tunica serosa and tunica mucosa 
 
of different organs. Mast cells play a central role in eliciting type 
I hypersensitivity reactions, but they have also been associated 
with autoimmune diseases, cancer and reactions against para- 
sites (1). 
A growing body of data that has accumulated during the last 
years has indicated that MC also have a central role in chronic 
inflammatory processes with different etiopathologies, often 
resulting in fibrosis. 
The presence of MC in the early stages of fibrosis in areas of 
tissue remodeling and repair was first observed by Paul Ehrlich 
in 1878, who hypothesized a role for MC in fibrosis (2). Since 
then, MC were proposed to participate in various fibrotic con- 
ditions such as scleroderma, chronic graft-versus-host disease 
(cGVHD), eosinophilic fasciitis, wound healing, idiopathic 
pulmonary fibrosis and ocular cicatricial pemphigoid (3-6). 
The hypothesis of a role of MC in fibrosis was strengthened 
since the recent observation that MC can produce cytokines (1, 
7) apart from the classical preformed mediators such as hista- 
mine, proteoglycans, proteolytic enzymes, and newly formed 
mediators such as prostaglandins, leukotriens and platelet ac- 
tivating factor (1). It was also shown that MC can be stimu- 
lated by cytokines and histamine-releasing factors in a chronic 
and slow fashion, which is probably characteristic of chronic 
inflammatory processes rather than acute anaphylactic ones (8- 
9). The MC ability in normal and pathologic tissues to produce 
  
  
type VIII collagen further supports their role in fibrosis (10). 
Fibroblasts and myofibroblasts are the key cells in tissue re- 
modeling. The close proximity of MC and fibroblasts in con- 
nective tissues enables the interaction between these two cell 
types. Fibroblasts have been shown to provide the microenvi- 
ronment for MC differentiation and survival. On the other 
hand, MC can affect fibroblasts through the release of various 
mediators with either fibrogenic or fibrolytic activities. Hista- 
mine, for example, can stimulate proliferation of skin fibro- 
blasts, and secretion of procollagen by these cells (11). The 
serine protease chymase secreted by MC can activate procolla- 
genase and cause connective tissue degradation (12). 
Fibrotic conditions are diseases characterized by increased fi- 
broblast proliferation and enhanced secretion of procollagen 
and extracellular matrix components. As a result, morphologi- 
cal and functional changes in tissues in various target organs 
appear. Examples of such disorders include scleroderma, 
cGVHD, eosinophilic fasciitis, atherosclerosis, ocular cicatri- 
cial pemphigoid, neurofibromatosis, rheumatoid arthritis, and 
wound healing and its abnormal manifestations, such as hyper- 
trophic scars andkeloids (13-17). The number of MC infibrotic 
diseases increases during the active inflammatory process, but 
decreases as the involved tissue turns into scar tissue. Although 
MC may be of a major importance in fibrosis, it should be kept 
in mind that the information gathered reflects only a small part 
of a more complex system in which many other components, in 
addition to MC and fibroblasts, interact. Other immune cells 
can, for example, influence fibroblast activity by secreting fi- 
brogenic cytokines that stimulate fibroblast proliferation and 
collagen production. This review presents current data about 
MC in some fibrotic conditions (Table 1), focusing on the pos- 
sible role of MC in fibroblast activation. 
SCLERODERMA 
• Scleroderma is an autoimmune disease of unknown eti- 
ology. It is characterized by diffuse fibrosis in the skin alone 
(morphea), or also in internal organs (systemic sclerosis). 
Table 1. Mast cell-related fibrotic conditions 
 
Excessive secretion of procollagen type I and fibronectin was 
found in these patients (18). The role of MC in scleroderma 
was addressed in several studies (19 and Refs therein). In- 
creased MC number was observed in the early inflammatory 
stage of the disease, neither in areas of uninvolved skin, nor 
in the late quiescent stage (20). Another study had demon- 
strated increased releasability of MC granules in affected skin 
in scleroderma (21). An increase in MC number and degranu- 
lation was found to precede the clinical signs of skin fibrosis 
in systemic sclerosis (22). Fibrogenic cytokines secreted from 
MC that may contribute to fibrosis in scleroderma are tumor 
necrosis factor-oc and interleukin-4 (IL-4). The latter was de- 
tected more frequently in sera of scleroderma patients than in 
controls (23). 
The possible role of MC in fibrosis has led to clinical trials 
using ketotifen, an inhibitor of MC mediator release, as a treat- 
ment for scleroderma (16). Although one study reported a ben- 
eficial effect of this drug in two patients with scleroderma (24), 
another, double-blind placebo-controlled clinical trial of keto- 
tifen in 24 patients failed to demonstrate a significant improve- 
ment (25). 
CHRONIC GRAFT-versus-HOST DISEASE 
• This condition is a serious complication of allogenic 
bone-marrow transplantation occurring 3 to 12 months after 
transplantation in up to 30% of patients. It is characterized by 
collagen deposition in various target organs, production of au- 
toantibodies, and immunodeficiency. The fibrotic processes 
cause scleroderma-like skin changes, pulmonary fibrosis, gas- 
trointestinal malabsorption, and severe keratoconjunctivitis 
sicca (26). 
A murine model of cGVHD was developed by intravenous in- 
jection of B10/D2 spleen cells to sublethally irradiated Balb/c 
mice (27). This model was obtained across minor histocom- 
patibility barriers and resembled the human disease. In fact, 
several weeks following injection, the histopathologic findings 
of dermal fibrosis, mononuclear infiltrate and loss of dermal 
fat resembled human cGVHD (28). In this model, connective 
tissue MC from kidney capsule, tongue, and peritoneal cavity 
were found to be completely degranulated just before fibrosis 
developed: a striking decrease of MC number was demonstrated 
from day 12 onwards, and a complete disappearance from day 
20 to day 120 when fibrosis was evident (29). Later on, MC 
reappeared and increased in numbers as the fibrotic processes 
gradually subsided. Therefore, it seems that a temporal rela- 
tion between MC activation and fibrosis appearance exists in 
this cGVHD model. 
To investigate the precise role of MC in cGVHD and to reveal 
a source of activating factors in this disease, the effect of spleno-   
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cytes from cGVHD mice on peritoneal MC was evaluated. 
Supernatants of these splenocytes induced MC activation mani- 
fested by a slow histamine release after 4-5 days of incubation. 
This activation was evident when the splenocytes were from 
early stage cGVHD mice with extensive fibrosis but not with 
mice whose cGVHD and fibrotic manifestations had resolved 
(30). Similar observations were made also in human cGVHD. 
In fact, supernatants of peripheral blood mononuclear cells 
from cGVHD patients displayed a histamine-releasing activ- 
ity towards rat peritoneal MC (31). Also, this MC activation 
had a slow onset and was continuous. MC histamine release 
was partially inhibited by the addition of an anti-IL-1 neutral- 
izing antibody, indicating that IL-1 is one of the histamine 
releasing factors contained in the supernatant (31, see also 8). 
In a recent study on cGVHD patients, a fivefold decrease in 
MC number from biopsies of involved skin compared to con- 
trols was found. This observation suggests that MC have de- 
granulated and contributed to the fibrotic process. Treatment 
of these patients with ketotifen for 3 months normalized MC 
count and correlated well with a general clinical improvement 
(32). In animal model, nedocromil sodium, an antiallergic drug 
with MC stabilizing properties, was administered to cGVHD 
mice for 18 days, beginning three days before the induction of 
the disease (6). Another group of mice was injected with com- 
pound 48/80 to activate MC. Nedocromil treatment normal- 
ized both peritoneal and skin MC number with a concomitant 
improvement of skin manifestations. On the other hand, com- 
pound 48/80 caused a complete disappearance of toluidine blue 
stainable peritoneal and skin MC, and induced skin changes 
resembling mild cGVHD (6). 
The above studies from both human disease and murine model 
demonstrate the important role of MC activation in the fibrotic 
process of cGVHD and clearly indicate that MC stabilization 
may be therapeutic target in this disease. 
EOSINOPHILIC FASCIITIS 
• Eosinophilic fasciitis (EF) is characterized by fibrosis 
of the middle parts of the limbs, sometimes extending to the 
trunk. Skin fibroblasts change into an activated form and pro- 
duce excessive collagen amounts (4). The hypothesis is that ac- 
tivated MC attract eosinophils by secreting eosinophil chemo- 
tactic factors and the eosinophils later on affect fibroblasts. 
However, studies have shown that MC may also act directly in 
promoting fibrosis in this disease. Infiltration consisted of MC 
and increased histamine levels were found in tissues in early 
stages of EF (33). Several reports have demonstrated the effi- 
cacy of cimetidine, a histamine (H,)-receptor antagonist, in the 
treatment of EF (34). The effect of this drug was probably a 
result of inhibition of MC degranulation and of antagonism to- 
wards the fibrogenic effects of histamine. 
WOUND HEALING 
• Wound healing (WH) is a complex process that starts 
immediately after injury and consists of inflammation, tissue 
granulation, and matrix formation (35). Following injury, there 
is initial increase in MC number around blood vessels followed 
by a plateau and return to baseline levels. MC participate in 
all stages of WH and affect fibroblasts mainly during the phase 
of matrix formation. 
Activity of MC in WH was evaluated in a rat model of inci- 
sional wounding, following the use of compound 48/80 to ac- 
tivate MC. An increased wound breaking strength and in- 
creased collagen deposition was detected following treatment 
with compound 48/80 (36). In another rat model of perforated 
mesentery, compound 48/80 significantly improved wound 
healing. However, this effect was not changed after addition 
of H,-receptor antagonist, implying that histamine was not re- 
sponsible for the improvement in healing (37). On the other 
hand, another study has demonstrated that while low doses of 
histamine increase collagen formation in rat skin wounds, high 
doses decreased it (38). In an in vitro model of wound consist- 
ing of MC co-cultured on 3T3 fibroblast monolayer, a "wound" 
was performed by scraping away half of the monolayer. Acti- 
vation of MC with compound 48/80 or with anti-IgE antibod- 
ies increased fibroblast migration and proliferation into the cell 
free area (39). Histamine was observed to be partially respon- 
sible for the MC enhancing effect on fibroblast migration and 
proliferation in this in vitro model (40). This may also be the 
case in keloids (11). 
IDIOPATHIC PULMONARY FIBROSIS (FIBROSING 
ALVEOL1TIS) 
• This lung disorder is manifested by inflammation and 
fibrosis of pulmonary interstitium and peripheral airspaces 
(41). It may be associated with asbestos inhalation, drugs 
(amiodarone, gold, busulphan, bleomycin) or with other chro- 
nic diseases, such as rheumatoid arthritis and scleroderma..In 
lung biopsies of patients with this disease, MC were found in 
fibrotic areas (42). High levels of histamine and tryptase were 
also detected in bronchoalveolar lavage (BAL) fluid (43), in- 
dicative of MC activation. 
Animal studies in which pulmonary fibrosis was induced by 
radiation, bleomycin or asbestos were performed to assess the 
role of MC. In these animal models, increased MC number was 
always found (44-46). In a more recent study of lung fibrosis 
induced by radiation, captopril, an angiotensin-converting 
enzyme inhibitor, reduced lung fibrosis concomitantly with 
reducing MC number (47). As with skin fibrotic diseases, it may 
be that a chronic low-grade MC activation is responsible for 
pulmonary fibrosis. A recent study has demonstrated the pre-   
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sence of histamine-releasing factor in B AL fluid of patients with 
pulmonary fibrosis, which caused the in vitro release of hista- 
mine, p-hexosaminidase and leukotriene C4 from MC (48). 
OCULAR CICATRICIAL PEMPHIGOID 
• Ocular cicatricial pemphigoid (OCP) is a chronic in- 
flammatory disease of presumed autoimmune etiology. It is 
characterized by chronic cicatrizing conjunctivitis and progres- 
sive conjunctival subepithelial fibrosis, which result in fornix 
shortening, symblepharon formation, trichiasis, distichiasis, 
meibomian duct obstruction and reduced tear supply to the 
ocular surface (14,15). The disease is bilateral and eventually 
results in blindness in a high proportion of these patients due 
to corneal scarring. No topical treatment is effective in stop- 
ping conjunctival scarring. High doses of systemic corticoster- 
oids, alone or in combination with systemic immunosuppres- 
sive therapy, are required to control the disease. One of the 
histopathological findings in the conjunctiva is considerable 
MC presence in the substantia propria inflammatory cell in- 
filtrate (14, 15). Furthermore, the ratio of connective tissue MC 
to mucosal MC was significantly higher in active and advanced 
OCP patients when compared with normal controls or with 
patients with a mild form of the disease (15). This observation 
is interesting since connective tissue MC have been implicated 
in other fibrotic diseases discussed herein. In this regard, re- 
cent data of involvement of MC and nerve growth factor in ver- 
nal conjunctivitis are also provocative (49, see also 13, 19). 
CONCLUSION 
The data gathered from in vivo studies on patients and from 
animal models show that MC may play an important role in 
fibrosis. In vitro studies have shown that MC mediators have 
the capacity to directly affect fibroblast migration, prolifera- 
tion and secretion. Further studies are needed to find the spe- 
cific MC activators which act in fibrosis and to understand the 
interaction between MC and fibroblasts under various patho- 
logical conditions. Thus MC could represent a novel target for 
the development of therapeutic strategies to treat fibrotic dis- 
ease (13, 16, 24, 25, 32, 34, 47). 
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